A Flechon

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. pmc Chemotherapy in advanced bladder cancer: current status and future
    Nabil Ismaili
    Medical Oncology, Centre régional d oncologie, Agadir, Morocco
    J Hematol Oncol 4:35. 2011
  2. pmc A rare case of advanced testicular seminoma in a 78-year-old man managed successfully with carboplatin based chemotherapy: a case report
    Nabil Ismaili
    Department of Medical Oncology at National Institute of Oncology, Rabat, Morocco
    Cases J 1:357. 2008
  3. pmc Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience
    Pierre Heudel
    Leon Berard Cancer Center, 28 rue Laennec, 69008 Lyon, France
    BMC Urol 9:5. 2009
  4. ncbi request reprint Chemotherapy practices and perspectives in invasive bladder cancer
    Aude Flechon
    Centre Leon Berard, Department of Medical Oncology, 28 rue Laennec, 69008 Lyon, France
    Expert Rev Anticancer Ther 6:1473-82. 2006
  5. ncbi request reprint [Surgery of residual masses after chemotherapy in patients with testicular cancer]
    Aude Flechon
    Departement de cancerologie medicale, Centre Leon Berard, Lyon
    Rev Prat 57:389-98. 2007
  6. ncbi request reprint [Gemcitabine and pemetrexed in genito-urinary tumors treatment]
    Aude Flechon
    Departement d Oncologie Medicale, Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 94:S116-21. 2007
  7. ncbi request reprint High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: the French experience
    A Flechon
    Groupe d Etude des Tumeurs Uro Génitales GETUG, French Federation of Cancer Centers, Paris, France
    Int J Cancer 83:844-7. 1999
  8. doi request reprint Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour
    Aude Flechon
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    BJU Int 106:779-85. 2010
  9. doi request reprint [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma]
    A Flechon
    Centre Leon Berard, Universite de Lyon, Departement d Oncologie Medicale, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 97:73-82. 2010
  10. ncbi request reprint Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers
    Aude Flechon
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Anticancer Drugs 17:705-8. 2006

Detail Information

Publications41

  1. pmc Chemotherapy in advanced bladder cancer: current status and future
    Nabil Ismaili
    Medical Oncology, Centre régional d oncologie, Agadir, Morocco
    J Hematol Oncol 4:35. 2011
    ..The purpose of this literature review is to highlight the role of chemotherapy in the management of advanced transitional cell carcinoma of the bladder...
  2. pmc A rare case of advanced testicular seminoma in a 78-year-old man managed successfully with carboplatin based chemotherapy: a case report
    Nabil Ismaili
    Department of Medical Oncology at National Institute of Oncology, Rabat, Morocco
    Cases J 1:357. 2008
    ..Germ cell tumours are uncommon in aged man. We present a rare case of metastatic seminoma of the testis associated with liver and renal insufficiencies in a 78-years-old man managed successfully with carboplatin based chemotherapy...
  3. pmc Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience
    Pierre Heudel
    Leon Berard Cancer Center, 28 rue Laennec, 69008 Lyon, France
    BMC Urol 9:5. 2009
    ..A retrospective review of our experience in management of patients with muscle-invasive or metastatic micropapillary bladder cancer was performed to better define the behavior of this disease...
  4. ncbi request reprint Chemotherapy practices and perspectives in invasive bladder cancer
    Aude Flechon
    Centre Leon Berard, Department of Medical Oncology, 28 rue Laennec, 69008 Lyon, France
    Expert Rev Anticancer Ther 6:1473-82. 2006
    ..Only a few patients have long-term nonevolutive disease. Research must be focused on the combination of chemotherapy and targeted drugs directed through gene methylation, cytokine-receptor activation and signaling pathways...
  5. ncbi request reprint [Surgery of residual masses after chemotherapy in patients with testicular cancer]
    Aude Flechon
    Departement de cancerologie medicale, Centre Leon Berard, Lyon
    Rev Prat 57:389-98. 2007
    ..Residual masses of pure seminoma are removed only when postoperative pet-scan evaluation is positive or when they have grown during the follow-up period. All surgical procedures must be performed in a reference center...
  6. ncbi request reprint [Gemcitabine and pemetrexed in genito-urinary tumors treatment]
    Aude Flechon
    Departement d Oncologie Medicale, Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 94:S116-21. 2007
    ..The combination of gemcitabine and 5-fuoruracile has modest activity in renal cell carcinoma. Pemetrexed is not indicating in genitor-urinary tumors, further evaluation in urothelial cancer is warranted...
  7. ncbi request reprint High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: the French experience
    A Flechon
    Groupe d Etude des Tumeurs Uro Génitales GETUG, French Federation of Cancer Centers, Paris, France
    Int J Cancer 83:844-7. 1999
    ..A European randomized trial, which studies the role of HDCT in the first-line salvage treatment of non-refractory disease, is ongoing. So far, HDCT is not a standard treatment of GCT...
  8. doi request reprint Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour
    Aude Flechon
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    BJU Int 106:779-85. 2010
    ....
  9. doi request reprint [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma]
    A Flechon
    Centre Leon Berard, Universite de Lyon, Departement d Oncologie Medicale, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 97:73-82. 2010
    ..The management of toxic effects is essential to ensure treatment compliance and patient quality of life. The present report describes in detail the adverse events associated with each therapeutic class and the management of side effects...
  10. ncbi request reprint Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers
    Aude Flechon
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Anticancer Drugs 17:705-8. 2006
    ..Whether this approach may increase survival is currently assessed in a randomized trial...
  11. doi request reprint Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
    A Flechon
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, Lyon Cedex 08, France
    Ann Oncol 22:2476-81. 2011
    ..In the evolution of metastatic castration-resistant prostate cancer (mCRPC), patients present visceral metastases with or without neuroendocrine differentiation in 20% of cases...
  12. ncbi request reprint Management of clinical stage I nonseminomatous germ-cell testis tumors
    Aude Flechon
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Expert Rev Anticancer Ther 3:21-30. 2003
    ..New imaging procedures also permit staging and prediction of outcome. Decision-making is shared between the patient and his oncologist. Economic issues are better understood but should be further studied...
  13. ncbi request reprint [Cancer of the testis: role of radiotherapy in 2003]
    S Clippe
    Departement de Radiotherapie, Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    Cancer Radiother 7:60s-69s. 2003
    ..Other treatment options are strict surveillance and adjuvant carboplatin based chemotherapy. None of these options are standard treatments. A strict attention must be directed on controlateral germ-cell tumors and second cancers...
  14. ncbi request reprint [Testis germ cell tumours: which chemotherapy, for which patients?]
    A Flechon
    Departement de cancerologie medicale, Centre Lóon Bérard, 28, rue Laennec, 69008 Lyon, France
    Ann Urol (Paris) 41:56-67. 2007
    ..Patients with stage I disease may receive one cycle of carboplatin. Salvage chemotherapy is based on the combination of ifosfamide, cisplatine and either vinblastine or paclitaxel...
  15. ncbi request reprint Pattern of relapse after first line treatment of advanced stage germ-cell tumors
    A Flechon
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Eur Urol 48:957-63; discussion 963-4. 2005
    ..We performed a retrospective analysis of first relapses after cisplatin-based chemotherapy in patients with advanced germ-cell tumors, in order to better define the appropriate follow-up...
  16. ncbi request reprint Importance of surgery as salvage treatment after high dose chemotherapy failure in germ cell tumors
    A Flechon
    Departments of Medical Oncology and Surgery, Centre Leon Berard, Lyon, France
    J Urol 165:1920-6. 2001
    ..The survival of patients with germ cell cancer after failed high dose chemotherapy is poor. We retrospectively reviewed the various treatment choices in this situation...
  17. ncbi request reprint [Is still there an indication for high-dose chemotherapy with hematopoietic stem-cell support in the treatment of germ-cell tumors?]
    A Flechon
    Centre Leon Berard, Departement d Oncologie Medicale, 28, rue Laennec, 69008 Lyon
    Bull Cancer 88:852-7. 2001
    ..Randomized trials are on going in these two settings. High dose chemotherapy is not actually a standard treatment in germ cell tumors...
  18. ncbi request reprint Results of a phase II study of carboplatin and etoposide in patients with progressive metastatic castration refractory prostate cancer (mCRPC) and neuro-endocrine differentiation
    A Flechon
    Centre Leon Berard, Lyon, France Centre Val d Aurelle, Montpellier, France Institut Curie, Paris, France Institut Paoli Calmette, Marseille, France Centre François Baclesse, Caen, France Hôpital européen Georges Pompidou, Paris, France Fondation Hopital Saint Joseph, Paris, France Hôpital Henri Mondor, Creteil, France
    J Clin Oncol 27:e16073. 2009
    ..5 X normal serum values and/or visceral metastases confirmed with immunihistochemical proof of neuro-endocrine differentiation on pathological sample...
  19. ncbi request reprint Prostate cancer: management of advanced disease
    J P Droz
    Centre Leon Berard, Department of Medical Oncology, Lyon, France
    Ann Oncol 13:89-94. 2002
  20. ncbi request reprint Intensive and timely chemotherapy, the key of success in testicular cancer
    A Flechon
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France
    Crit Rev Oncol Hematol 37:35-46. 2001
    ..In conclusion, high-dose chemotherapy is not a standard treatment for different situations. New strategies are needed to improve the survival rate of poor prognosis germ cell tumor patients...
  21. ncbi request reprint [Bladder cancer chemotherapy practice study]
    Christine Clippe
    Departement d Oncologie Medicale, Centre Leon Berard, Lyon, France
    Prog Urol 12:609-14. 2002
    ..To study chemotherapy practice in invasive bladder cancer in a cancer centre (Centre Léon Bérard)...
  22. doi request reprint Management of brain metastases from germ cell tumors: a single center experience
    H J Boyle
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Oncology 85:21-6. 2013
    ..Brain metastases from germ cell tumors (GCT) are rare and treatment has not yet been standardized...
  23. ncbi request reprint Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group
    K Fizazi
    Institut Gustave Roussy, Villejuif, Centre Leon Berard, Lyon, and Centre Val d Aurelle, Montpellier, France
    J Clin Oncol 19:2647-57. 2001
    ..To assess the value of postsurgery chemotherapy in patients with disseminated nonseminomatous germ-cell tumors (NSGCTs) and viable residual disease after first-line cisplatin-based chemotherapy...
  24. ncbi request reprint Management of post-chemotherapy residual masses in advanced seminoma
    Aude Flechon
    Department of Medical Oncology, Centre Léon Bérnard, Lyon, France
    J Urol 168:1975-9. 2002
    ..We studied the resection of post-chemotherapy residual masses (20% to 80%) of advanced seminoma complicated by extensive fibrosis, in which active disease appears in 10% to 20% of cases...
  25. ncbi request reprint Docetaxel-based chemotherapy in elderly patients (≥ 75 years) with castration resistant prostate cancer (CRPC): A French National study of 175 patients
    E Bompas
    Centre Rene Gauducheau, Saint Herblain, France Institut Gustave Roussy, Villejuif, France Centre Antoine Lacassagne, Nice, France Hôpital européen Georges Pompidou, Paris, France Centre Val d Aurelle, Marseille, France Institut Paoli Calmettes, Marseille, France Institut Curie, Paris, France Centre Leon Berard, Lyon, France Centre François Baclesse, Rouen, France
    J Clin Oncol 26:5145. 2008
    ..5145 Background: Although docetaxel-based chemotherapy is a standard in CRPC, only limited data is available in elderly patients (pts) with CRPC treated with chemotherapy...
  26. doi request reprint Treatment of uncommon malignant tumours of the bladder
    H Boyle
    Department of Medical Oncology, Centre Leon Berard, Lyon bClaude Bernard Lyon1 University, Lyon, France
    Curr Opin Urol 21:309-14. 2011
    ..Nevertheless, its variants and less common types represent 20% of all bladder cancers. The objective was to update the recent publications on these rare diseases and to draw conclusions for clinical management...
  27. doi request reprint Management of advanced germ-cell tumors of the testis
    Aude Flechon
    Medical Oncology, Comprehensive Cancer Centre, Léon Bérard Claude Bernard Lyon 1 University, Lyon, France
    Nat Clin Pract Urol 5:262-76. 2008
    ..Owing to the complexity of treatment and the multidisciplinary approach required, patients with advanced germ-cell tumors should be managed in high-volume centers with experience of treating large numbers of patients...
  28. ncbi request reprint [Chemotherapy of neuroendocrine tumors]
    Jean Pierre Droz
    Département de cancérologie médicale Centre Léon Bérard 69373 Lyon
    Rev Prat 52:285-9. 2002
    ..Indication of chemotherapy must be balanced with indications of biotherapies and embolization...
  29. ncbi request reprint [Metastatic prostate cancer]
    Jean Pierre Droz
    Departement de cancerologie medicale, Centre Leon Berard, 69373 Lyon 08
    Rev Prat 53:2258-62. 2003
    ..Androgen deprivation is the first-line treatment, impotency and osteoporosis being the main side effects. Other treatments are radiotherapy, radiopharmaceutics and chemotherapy. The most important treatment issue is quality of life...
  30. ncbi request reprint Pharmacokinetic (PK) analysis of two dosing schedules of the angiokinase inhibitor BIBF 1120 in patients with hormone- refractory prostate cancer (HRPC) who progressed after docetaxel treatment
    J Droz
    Centre Leon Berard, Lyon, France Centre Régional François Baclesse, Caen, France Boehringer Ingelheim France, Reims, France Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany Hôpital Européen Georges Pompidou, Paris, France
    J Clin Oncol 26:14578. 2008
    ..This randomized, open-label, multicenter Phase II study evaluated the efficacy, safety and PK of two doses of BIBF 1120 in patients with metastatic HRPC that had progressed after docetaxel therapy...
  31. ncbi request reprint Management of brain metastases from germ cell tumours
    H J Boyle
    Centre Leon Berard, Lyon, France Hopital Wertheimer, Bron, France
    J Clin Oncol 26:16076. 2008
    ..16076 Background: Brain metastases (BM) from germ cell tumours (GCT) are rare events for which treatment is not yet standardized...
  32. ncbi request reprint Major prognostic value of modeled AUChCG-AFP, a dynamic kinetic marker characterizing tumor marker decline of nonseminomatous germ cell tumors (NSGCT) intermediate-poor-risk patients according to the IGCCCG
    H Boyle
    Centre Leon Berard, Lyon, France Université Lyon 1, Faculté Médecine Lyon Sud, Oullins, France Faculté Medecine Lyon Sud, Centre Leon Berard, Oullins, France AP HP, Faculté Médecine Lyon Sud, Oullins, France Hopital Saint Luc Saint Joseph, Lyon, France
    J Clin Oncol 27:5085. 2009
    ..We propose to model patient's AFP and hCG decline profiles in order to calculate area under the curve of marker concentrations versus time (AUChCG-AFP) and to test its prognostic value...
  33. doi request reprint [Uncommon bladder tumours]
    H Boyle
    Universite Claude Bernard, Centre Leon Berard, Departement de cancerologie medicale, Lyon I, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 97:51-7. 2010
    ..The treatment is the same as this of lymphomas of other location and of the same histology. Attention must be drawn on a precise evaluation of the pathological pattern and of the disease extension...
  34. doi request reprint [The role of chemotherapy in the management of bladder cancer]
    N Ismaili
    Departement d Oncologie Medicale, France
    Prog Urol 21:369-82. 2011
    ..The role of targeted therapies alone, in combination with chemotherapy, and in maintenance, is being evaluated...
  35. ncbi request reprint Gemcitabine in bladder cancer
    Fadi El Karak
    Centre Leon Berard, Department of Medical Oncology, 28 rue Laennec, 69008, Lyon, France
    Expert Opin Pharmacother 8:3251-6. 2007
    ..This article reviews most of the studies performed in order to promote the usefulness of gemcitabine in bladder cancer...
  36. ncbi request reprint Small cell cancer of the bladder: The Léon-Bérard Cancer Center experience
    I N Nabil
    Centre Leon Berard, Lyon, France
    J Clin Oncol 26:16147. 2008
    ..16147 Background: Small cell bladder carcinoma is an uncommon tumour. In this retrospective study we report our experience dealing with this disease at Léon-Bérard Cancer Center...
  37. ncbi request reprint Complete response of an HIV negative gastric Kaposi's sarcoma (KS) patient with peritoneal carcinomatosis by liposomal daunorubicin treatment
    A Flechon
    Oncologie Médicale, H pital Edouard Herriot, Lyon, France
    Ann Oncol 12:275-6. 2001
    ..The patient is in complete remission six months after the end of treatment. Liposomal daunorubicin is a promising treatment in the non HIV patient with visceral KS...
  38. ncbi request reprint Coagulopathy in prostate cancer
    C De la Fouchardiere
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Neth J Med 61:347-54. 2003
    ..Other coagulopathies associated with prostate cancer are thrombocytopenic thrombotic purpura, thrombosis, Trousseau's syndrome and acquired factor VIII inhibitor development...
  39. doi request reprint Pleural metastasis in a patient with bladder cancer
    Nathalie Bonnin
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    J Clin Oncol 26:329-30. 2008
  40. doi request reprint Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor
    Benoit You
    Universite de Lyon, Lyon, France
    Urology 76:423-9.e2. 2010
    ..We assessed the predictive values of areas under the curve of hCG (AUC(hCG)) and AFP (AUC(AFP)) of modeled concentration-time equations on progression-free survival (PFS)...
  41. doi request reprint Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study
    Florence Joly
    Departement d Oncologie Medicale, Centre François, Baclesse, France
    Clin Genitourin Cancer 7:E28-33. 2009
    ..There is no standard second-line chemotherapy for patients who relapse with advanced urothelial carcinoma. A GETUG phase II clinical trial was designed to evaluate the response rate and the palliative clinical benefit of weekly paclitaxel...